0001656472-24-000023.txt : 20240305 0001656472-24-000023.hdr.sgml : 20240305 20240305171335 ACCESSION NUMBER: 0001656472-24-000023 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shlimak Anna CENTRAL INDEX KEY: 0001804953 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38403 FILM NUMBER: 24722223 MAIL ADDRESS: STREET 1: 720 KING STREET WEST, SUITE 320 CITY: TORONTO STATE: A6 ZIP: M5V 2T3 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cronos Group Inc. CENTRAL INDEX KEY: 0001656472 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 BUSINESS PHONE: (416) 504-0004 MAIL ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 FORMER COMPANY: FORMER CONFORMED NAME: PharmaCan Capital Corp. DATE OF NAME CHANGE: 20151021 4 1 wk-form4_1709676787.xml FORM 4 X0508 4 2024-03-01 0 0001656472 Cronos Group Inc. CRON 0001804953 Shlimak Anna 111 PETER STREET, SUITE 300 TORONTO A6 M5V 2H1 ONTARIO, CANADA 0 1 0 0 See Remarks 0 COMMON SHARES 2024-03-01 4 M 0 7337 0 A 120020 D COMMON SHARES 2024-03-01 4 F 0 2175 2.08 D 117845 D RESTRICTED STOCK UNITS 2024-03-01 4 M 0 7337 0 D COMMON SHARES 7337 195678 D Each restricted stock unit ("RSU") represents a contingent right to receive one common share of Cronos Group Inc. Due to an inadvertent error, the Form 4 filed by the Reporting Person on May 15, 2023 incorrectly reported the amount of securities beneficially owned following reported transaction(s). This inadvertent error caused the amount of securities beneficially owned to be overstated by 21,403 shares. The new amount reported in Column 5 reports the correct amount of securities beneficially owned following reported transaction(s). On March 1, 2021, the Reporting Person was granted 22,009 RSUs, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. Due to an inadvertent error, the Form 4 filed by the Reporting Person on May 15, 2023 incorrectly reported the number of derivative securities beneficially owned following reported transaction(s). This inadvertent error caused the number of derivative securities beneficially owned to be understated by 153,772 shares. The new amount reported in Column 9 reports the correct number of derivative securities beneficially owned following reported transaction(s). Senior Vice President, Corporate Affairs and Strategy /s/ Aaron Werner, as attorney-in-fact for Anna Shlimak 2024-03-05